Reactivation of chronic hepatitis B infection related to imatinib mesylate therapy in patients with chronic myeloid leukemia: two cases report and literatures review.
- Author:
Ya-Dan WANG
1
;
Guo-Hui CUI
;
Yong YOU
;
Mian LI
;
Jia XIA
;
Yu HU
Author Information
- Publication Type:Case Reports
- MeSH: Adult; Benzamides; adverse effects; therapeutic use; Hepatitis B; virology; Hepatitis B virus; drug effects; physiology; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; drug therapy; virology; Male; Piperazines; adverse effects; therapeutic use; Pyrimidines; adverse effects; therapeutic use; Virus Activation; drug effects
- From: Chinese Journal of Hematology 2012;33(9):743-746
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo probe the cause for triggering HBV reactivation and possible management of the chronic hepatitis B individuals received imatinib.
METHODSThis study presented two cases of transient hepatitis B virus (HBV) reactivation and hepatic dysfunction during oral imatinib for chronic myeloid leukemia (CML) and made a literatures review about the pathogenesis, possible prophylactic and therapeutic management of such chronic hepatitis B individuals receiving imatinib.
RESULTSTwo CML patients, without prior liver dysfunction but with chronic HBV infection, suffered from transient HBV reactivation occurred during oral imatinib. Both of them finally obtained good outcome following the additional oral nucleotide antiviral therapy.
CONCLUSIONIt remained unclear whether imatinib induced the reactivation of HBV in patients with a latent HBV infection. From our study, all candidates receiving oral imatinib should be screened for HBsAg and anti-HBc antibodies prior to initiation of imatinib. Prophylactic antiviral therapy should be offered to HBV-infected individuals along with a close monitoring for signs of reactivation.
